{"id":"W4400143742","doi":"10.1016/j.annonc.2024.05.055","title":"44P BOLD-100-001: A phase II study of BOLD-100 in combination with FOLFOX in advanced mCRC patients that have failed at least two prior lines of therapy","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"Translational Research in Oncology; iCo Therapeutics (Canada); Innovative Targeting Solutions (Canada); McGill University; Princess Margaret Cancer Centre; University Health Network; Jewish General Hospital; McMaster University; Ottawa Regional Cancer Foundation; Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; FOLFOX; Internal medicine; Oncology; Phases of clinical research; Oxaliplatin; Colorectal cancer; Chemotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001176247,0.001580134,0.002503092,0.0005643024,0.0005008533,0.001303077,0.001087638,0.001751945,0.005958538],"category_scores_gemma":[0.0008277699,0.0007888844,0.001677889,0.0004463579,0.001311532,0.0009347363,0.0005320015,0.006734967,0.001412369],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001160163,"about_ca_system_score_gemma":0.002050905,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002469081,"about_ca_topic_score_gemma":0.006363887,"domain_scores_codex":[0.9996957,0.000110438,0.00001256884,0.00005271417,0.00002656093,0.0001021306],"domain_scores_gemma":[0.999426,0.00008171543,0.00006145128,0.00004486373,0.00003010153,0.0003558813],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4852893,0.1215915,0.005542571,0.001813051,0.003641709,0.0005981956,0.0005441618,0.0120204,0.08928727,0.001355657,0.0218346,0.2564816],"study_design_scores_gemma":[0.5038617,0.4676389,0.007741448,0.00009011201,0.0007544944,0.0004533946,0.000094995,0.00328747,0.00684819,0.0004629079,0.008668246,0.00009820919],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9844945,0.002733498,0.0009421399,0.00270891,0.0003844425,0.002073807,0.002217018,0.0003610949,0.004084612],"genre_scores_gemma":[0.970934,0.004381163,0.004911506,0.002624031,0.0003084506,0.002408564,0.005415948,0.0001529382,0.008863301],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005958538,"threshold_uncertainty_score":0.01993328,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05152543002927577,"score_gpt":0.4220904643900035,"score_spread":0.3705650343607277,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}